晚期非小细胞肺癌维持治疗进展

摘要/Abstract

摘要： 晚期非小细胞肺癌（NSCLC）标准一线化疗方案的疗效已达到了一个平台期。研究证实化疗药物、分子靶向药物维持治疗可延长晚期NSCLC患者的生存期。免疫治疗成为晚期NSCLC的维持治疗，还需进一步研究证实。

Abstract: The efficacy of the standard firstline chemotherapy regimen for advanced nonsmall cell lung cancer (NSCLC) has reached a plateau. Study confirmed that chemotherapy drugs and molecular targeted drug maintenance treatment can prolong the survival of patients with advanced NSCLC. Immunotherapy has become a maintenance treatment for advanced NSCLC, and further research is needed to confirm its efficacy.

Key words: Carcinoma, nonsmallcell lung cancer, Drug therapy, Molecular targeted therapy, Immunotherapy

温珍平, 韩雅玲. 晚期非小细胞肺癌维持治疗进展[J]. 国际肿瘤学杂志, 2016, 43(2): 148-.

Wen-Zhen-Ping, HAN Ya-Ling. Progress of maintenance therapy for advanced nonsmallcell lung cancer[J]. Journal of International Oncology, 2016, 43(2): 148-.

参考文献

［1］ Fidias P, Dakhil S, Lyss A, et al. Phase Ⅲ study of immediate versus delayed docetaxel after induction therapy with gemcitabine plus carboplatin in advanced nonsmallcell lung cancer: updated report with survival［J］. J Clin Oncol, 2009, 27(4): 591598. ［2］ Belani CP, Brodowicz T, Ciuleanu TE, et al. Quality of life in patients with advanced nonsmallcell lung cancer given maintenance treatment with pemetrexed versus placebo (H3EMCJMEN): results from a randomised, doubleblind, phase 3 study［J］. Lancet Oncol, 2012,13(3): 292299. DOI: 10.1016/S14702045(11)703394. ［3］ PazAres LG, de Marinis F, Dediu M, et al. PARAMOUNT: Final overall survival results of the phase Ⅲ study of maintenance pemetrexed versus placebo immediately after induction treatment with pemetrexed plus cisplatin for advanced nonsquamous nonsmallcell lung cancer［J］. J Clin Oncol， 2013, 31(23): 28952902. DOI: 10.1200/JCO.2012.47.1102. ［4］ Perol M, Chouaid C, Perol D, et al. Randomized, phase Ⅲ study of gemcitabine or erlotinib maintenance therapy versus observation, with predefined secondline treatment, after cisplatingemcitabine induction chemotherapy in advanced nonsmallcell lung cancer［J］. J Clin Oncol, 2012, 30(28): 35163524. DOI: 10.1200/JCO.2011.39.9782. ［5］刘萍. 替吉奥维持治疗晚期非小细胞肺癌临床疗效观察［J］. 中国全科医学, 2013, 16(9):10381040. DOI: 10.3969/j.issn.10079572.2013.09.025 ［6］胡欣, 李光明, 文世民, 等. 局部晚期非小细胞肺癌维持化疗的疗效评价［J］. 肿瘤, 2010, 30(4): 343346. DOI: 10.3781/j.issn.10007431.2010.04.015 ［7］马晓丽, 张建清, 杨媚, 等. 厄洛替尼维持治疗晚期非小细胞肺癌的系统评价［J］. 中华肿瘤防治杂志, 2014, 21(10): 786791. ［8］ Zhang L, Ma S, Song X, et al. Gefitinib versus placebo as maintenance therapy in patients with locally advanced or metastatic nonsmallcell lung cancer (INFORM; CTONG 0804): a multicentre, doubleblind randomised phase 3 trial［J］. Lancet Oncol， 2012, 13(5): 466475. DOI: 10.1016/S14702045(12)701171. ［9］ Zhao H, Fan Y, Ma S, et al. Final overall survival results from a phase Ⅲ, randomized, placebocontrolled, parallelgroup study of gefitinib versus placebo as maintenance therapy in patients with locally advanced or metastatic nonsmallcell lung cancer (INFORM; CTONG 0804)［J］. J Thorac Oncol， 2015, 10(4): 655664. DOI: 10.1097/JTO.0000000000000445. ［10］ Crinò L, Dansin E, Garrido P, et al. Safety and efficacy of firstline bevacizumabbased therapy in advanced nonsquamous nonsmallcell lung cancer (SAiL, MO19390): a phase 4 study［J］. Lancet Oncol， 2010, 11(8):733740. DOI: 10.1016/S14702045(10)701510. ［11］ Barlesi F, Scherpereel A, Rittmeyer A, et al. Randomized phase Ⅲ trial of maintenance bevacizumab with or without pemetrexed after firstline induction with bevacizumab, cisplatin, and pemetrexed in advanced nonsquamous nonsmallcell lung cancer: AVAPERL (M022089)［J］. J Clin Oncol， 2013, 31(24): 30043011. DOI: 10.1200/JCO.2012.42.3749. ［12］ Pirker R, Pereira JR, Szczesma A, et al. Cetuximab plus chemotherapy in patients with advanced nonsmallcell lung cancer (FLEX): an openlabel randomized phase Ⅲ trial ［J］.Lancet, 2009, 373(9674): 15251531. DOI: 10.1016/S01406736(09)605699. ［13］ Shi SB, Ma TH, Li CH et al．Effect of maintenance therapy with dendritic cells: cytokineinduced killer cells in patients with advanced nonsmall cell lung cancer［J］. Tumori, 2012, 98(3): 314319. DOI: 10.1700/1125.12398. ［14］薛鸣, 郭明坤. CIK细胞联合白细胞介素2对非小细胞肺癌患者免疫功能及生命质量的影响［J］. 国际肿瘤学杂志, 2015, 42(2): 8890. DOI:10.3760/cma.j.issn.1673422X.2015.02.003. ［15］ Butts C, Maksymiuk A, Goss G, et al. Updated survival analysis in patients with stage ⅢB or Ⅳ nonsmallcell lung cancer receiving BLP25 liposome vaccine ( LBLP25): phase ⅡB randomized, multicenter, openlabel trial［J］. J Cancer Res Clin Oncol, 2011, 137(9): 13371342. DOI: 10.1007/s0043201110033. ［16］ Butts C, Socinski MA, Mitchell PL, et, al Tecemotide (LBLP25) versus placebo after chemoradiotherapy for stage Ⅲ nonsmallcell lung cancer (START): a randomised, doubleblind, phase 3 trial［J］. Lancet Oncol， 2014, 15(1): 5968. ［17］ Mitchell P, Thatcher N, Socinski MA, et al. Tecemotide (LBLP25)in unresectable stage Ⅲ nonsmallcell lung cancer in the phase Ⅲ START study: updated overall survival and biomarker analyses［J］. Ann Oncol， 2015, 26(6): 11341142. DOI: 10.1093/annonc/mdv104. ［18］ Zitvogel L, Kroemer G. Targeting pd1/pdl1 interactions for cancer immunotherapy［J］. Oncoimmunology, 2012, 1(8): 12231225. DOI: 10.4161/onci.21335. ［19］ Giaccone G, Bazhenova LA, Nemunaitis J, et al. A phase Ⅲ study of belagenpumatucelL therapeutic tumor cell vaccine for nonsmall cell lung cancer(NSCLC)［C］. Amsterdam：ESMO, 2013，abstract2.

[1]	钱晓涛, 石子宜, 胡格, 吴晓维. Ⅲ~ⅣA期食管鳞状细胞癌放化疗后行巩固化疗的疗效：一项真实世界临床研究[J]. 国际肿瘤学杂志, 2024, 51(6): 326-331.
[2]	郭泽浩, 张俊旺. PFDN及其亚基在肿瘤发生发展中的作用[J]. 国际肿瘤学杂志, 2024, 51(6): 350-353.
[3]	王盈, 刘楠, 郭兵. 抗体药物偶联物在转移性乳腺癌治疗中的研究进展[J]. 国际肿瘤学杂志, 2024, 51(6): 364-369.
[4]	高凡, 王萍, 杜超, 褚衍六. 肠道菌群与结直肠癌非手术治疗的相关研究进展[J]. 国际肿瘤学杂志, 2024, 51(6): 376-381.
[5]	王丽, 刘志华, 杨伟洪, 蒋凤莲, 李全泳, 宋浩杰, 鞠文东. ROS1突变肺腺鳞癌合并脑梗死为主要表现的Trousseau综合征1例[J]. 国际肿瘤学杂志, 2024, 51(6): 382-384.
[6]	范志鹏, 余静, 胡静, 廖正凯, 徐禹, 欧阳雯, 谢丛华. 炎症标志物的变化趋势对一线接受免疫联合化疗的晚期非小细胞肺癌患者预后的预测价值[J]. 国际肿瘤学杂志, 2024, 51(5): 257-266.
[7]	王俊毅, 洪楷彬, 纪荣佳, 陈大朝. 癌结节对结直肠癌根治性切除术后肝转移的影响[J]. 国际肿瘤学杂志, 2024, 51(5): 280-285.
[8]	顾芳萌, 徐晨阳, 雷大鹏. 人工智能辅助电子喉镜检查在喉癌及喉癌前病变诊治中的研究进展[J]. 国际肿瘤学杂志, 2024, 51(5): 303-307.
[9]	王培鑫, 赵军, 徐世红, 姜朝阳, 王小强, 杨红娟. 铁死亡相关机制在骨肉瘤中的应用进展[J]. 国际肿瘤学杂志, 2024, 51(5): 308-311.
[10]	张文馨, 夏泠, 彭晋, 周福祥. 甲胎蛋白升高型胃肝样腺癌1例并文献复习[J]. 国际肿瘤学杂志, 2024, 51(5): 312-315.
[11]	王昆, 周中新, 臧其威. 血清TGF-β1、VEGF水平对非小细胞肺癌患者单孔胸腔镜根治术后复发的预测价值[J]. 国际肿瘤学杂志, 2024, 51(4): 198-203.
[12]	杨毫, 施贵冬, 张程城, 张跃, 张力文, 付茂勇. 信迪利单抗与替雷利珠单抗在进展期食管鳞状细胞癌新辅助治疗中的疗效及安全性对比[J]. 国际肿瘤学杂志, 2024, 51(4): 210-216.
[13]	姚益新, 沈煜霖. 血清SOCS3、TXNIP水平对肝细胞癌TACE治疗预后的预测价值[J]. 国际肿瘤学杂志, 2024, 51(4): 217-222.
[14]	胡婷婷, 王越华. 电子鼻与线虫鼻——新型早期癌症筛查工具[J]. 国际肿瘤学杂志, 2024, 51(4): 223-226.
[15]	萨蔷, 徐航程, 王佳玉. 乳腺癌免疫治疗研究进展[J]. 国际肿瘤学杂志, 2024, 51(4): 227-234.